63. H7N9 Replikins Completely Synthetic Vaccine Ready Now for Testing
April 15, 2013
To be presented April 22nd-25th at Booth 3456 BIO Intnl. Conference, Chicago
London April 15, 2013. Bioradar UK Ltd and Replikins Ltd announced in a press release on April 9th that two H7N9 completely synthetic Replikins vaccines, both with long-term prevention goals and acute short-term blocking capacity, are now ready for testing: one for H7N9 alone, the other for H7N9 plus the other common influenza strains. This early vaccine availability, in contrast to the projections by other companies of 7 months or longer before vaccines are available, provides time for the first time to explore the actual prevention of pandemics (1-3).
Details will be provided at the BIO International Conference April 22nd-25th at Booth #3456, BIO International Conference, Chicago.
The basis for these new vaccines is similar to those the Companies used in manufacturing in 7 days by solid phase synthesis a successful Replikins H5N1 vaccine in chickens, shipping the vaccine freeze dried, and administering via the respiratory tract (4). Significantly, in addition to stopping the virus in vivo, excretion of the virus was completely prevented, thus potentially interfering with the build-up of virus reservoirs which encourage mutations.
- Nature Precedings. Bogoch et al, doi:10.1038/npre.2012.6952.1
(see also seven additional Nature Precedings Publications, Bogoch 2011-2012. http://precedings.nature.com/users/549471c7b195af1864d2f1b1996f60642.
- Dr. Sanjay Gupta of CNN Reports on Replikins (www.replikins.com)
- Jackwood et al. Avian Diseases 53(4): 613-617, 2009